ZIVO Bioscience, Inc. (ZIVO) Stock Price & Analysis
ZIVO Bioscience, Inc. (ZIVO) — price $5.50 (0.00%), as of the Nov 18, 2026 trading session; market cap $23.2M.
Educational signal · not a buy or sell recommendation · How to read this
ZIVO Bioscience, Inc. · ZIVO
ZIVO Bioscience, Inc. is a biotechnology company focused on the research and development of bioactive ingredients derived from proprietary algae cultures. The company aims to license and sell these ingredients to manufacturers in the animal, human, dietary supplement, and medical food sectors.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.50 | |
| Change on the day | 0.00% | |
| 52-week range | $1.11 – $12.04 | |
| Market capitalisation | $23.2M | — |
| Shares traded on the day | 529 |
Price & events
Other perspectives
Council score for ZIVO Bioscience (ZIVO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ZIVO Bioscience (ZIVO), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ZIVO Bioscience, Inc. (ZIVO) is the company analyzed here. It employs 7 people and is led by John Bernard Payne. In Q3 FY2025 it reported revenue of $65,625 and net income of -$1M. The market values it at $23.2M.
What do the latest results show for ZIVO Bioscience (ZIVO)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $65,625. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $65,625 | -$1M | -$0.27 (diluted) |
What are the financial strengths and risks for ZIVO Bioscience (ZIVO)?
Short answer · as of
The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 159.1% · current ratio 0.10 · earnings yield -23.0% · free-cash-flow yield -11.1%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at ZIVO Bioscience (ZIVO)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.19M · EPS -1.08 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.19M
- EPS estimate
- $-1.08
Measured against a quoted price of $5.50 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZIVO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ZIVO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About ZIVO
These answers are editorial: 1 of these 8 answers is drawn from the ZIVO research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ZIVO a good stock to buy?
Stock Expert AI does not rate ZIVO buy, sell or hold. ZIVO Bioscience, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZIVO stock price today?
The last price recorded for ZIVO Bioscience, Inc. (ZIVO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ZIVO?
ZIVO Bioscience, Inc. faces several risks inherent to the biotechnology industry and its specific business model. These include the risk of failing to secure licensing agreements for its bioactive ingredients, competition from larger and more established companies, regulatory hurdles and lengthy approval processes, and the need for additional funding to support its research and development efforts.
What are the key factors to evaluate for ZIVO?
Evaluate ZIVO on fundamentals, analyst consensus, and risk factors. Operates in the biotech and agtech sectors, targeting high-growth markets for natural health solutions. Not financial advice.
How frequently does ZIVO data refresh on this page?
ZIVO's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZIVO's recent stock price performance?
ZIVO Bioscience, Inc. (ZIVO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary algae strains and bioactive ingredients. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZIVO overvalued or undervalued right now?
ZIVO Bioscience, Inc. (ZIVO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZIVO before investing?
Before investing in ZIVO Bioscience, Inc. (ZIVO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 7 from Financial Modeling Prep (FMP) and 10 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com